|Chemical and physical data|
|Molar mass||310.430 g/mol|
|3D model (Jmol)||Interactive image|
Plomestane (INN, USAN) (former developmental code name MDL-18,962), also known as propargylestrenedione (PED), as well as 10-propargylestr-4-ene-3,17-dione, is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent for the treatment of breast cancer. It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration. However, development of the drug for clinical use was halted due to "technical issues" and it was never marketed.
Plomestane has weak androgenic properties.
- F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1635. ISBN 978-0-412-46630-4. Retrieved 19 May 2012.
- Dr. Ian Morton; Ian K. M. Morton; Judith M. Hall; Dr. Judith Hall (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer. p. 227. ISBN 978-0-7514-0499-9. Retrieved 20 May 2012. Cite uses deprecated parameter
- Bentham Science Publishers (June 1995). Current Pharmaceutical Design. Bentham Science Publishers. p. 45. Retrieved 20 May 2012.
- Richard B. Kreider; Brian C. Leutholtz; Frank I. Katch; Victor L. Katch (2009). Exercise and Sport Nutrition. Exercise & Sport Nutrition. p. 350. ISBN 978-0-9742965-6-2. Retrieved 20 May 2012. Cite uses deprecated parameter
- Kelloff GJ, Lubet RA, Lieberman R, et al. (January 1998). "Aromatase inhibitors as potential cancer chemopreventives". Cancer Epidemiology, Biomarkers & Prevention. 7 (1): 65–78. PMID 9456245.
- Carmen Avendaño; J. Carlos Menéndez (4 June 2008). Medicinal Chemistry of Anticancer Drugs. Elsevier. p. 69. ISBN 978-0-444-52824-7. Retrieved 20 May 2012.